POEMS综合征:诊断、风险分层与管理更新
本文综述POEMS综合征的诊断标准、风险分层与治疗策略。诊断需满足三大主要标准中的三条(必须包括多发性神经根神经病和克隆性浆细胞病)及至少一条次要标准。风险分层基于临床表型而非分子标志物,风险因素包括低血清白蛋白、年龄、胸腔积液、肺动脉高压和估算肾小球滤过率降低。治疗上,局限性浆细胞瘤首选放疗,弥漫性病变或骨髓广泛受累者接受全身治疗,烷化剂和来那度胺为主要药物。
要点
- 诊断需满足三条主要标准(必须含多发性神经根神经病和克隆性浆细胞病)及至少一条次要标准
- 风险分层基于临床表型,风险因素包括低白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低
- 局限性浆细胞瘤首选放疗,弥漫性病变或骨髓广泛受累者接受全身治疗
核心结论
- 及时识别并同时给予支持治疗和针对浆细胞的治疗可获得最佳结局。
研究设计与样本
- 综述,总结POEMS综合征的诊断标准、风险分层和治疗管理。
主要发现
- 主要标准为多发性神经根神经病、克隆性浆细胞病、硬化性骨病变、血管内皮生长因子升高和Castleman病。
- 次要特征包括器官肿大、内分泌病、特征性皮肤改变、视乳头水肿、血管外容量负荷过重和血小板增多。
- 风险因素包括低血清白蛋白、年龄、胸腔积液、肺动脉高压和估算肾小球滤过率降低。
关键数值与推荐
- 诊断需三条主要标准,其中必须包括多发性神经根神经病和克隆性浆细胞病,并至少一条次要标准。
- 风险分层限于临床表型而非特定分子标志物。
- 局限性浆细胞瘤一线治疗为放疗;弥漫性硬化性病变或骨髓广泛受累者应接受全身治疗。
- 糖皮质激素为暂时性治疗,烷化剂和来那度胺为治疗支柱,烷化剂可采用低剂量常规治疗或作为干细胞移植的高剂量预处理。
- 沙利度胺和硼替佐米有活性,但需权衡其加重周围神经病变的风险;达雷妥尤单抗联合方案基于病例系列似乎有前景。
临床怎么用
- 局限性浆细胞瘤患者一线治疗为放疗。
- 弥漫性硬化性病变或骨髓广泛受累者应接受全身治疗。
- 糖皮质激素为暂时性治疗,烷化剂和来那度胺为主要治疗药物。
- 沙利度胺和硼替佐米有活性,但需权衡其加重周围神经病变的风险。
- 达雷妥尤单抗联合方案基于病例系列似乎有前景。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: POEMS syndrome is a life-threatening condition due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder, sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. DIAGNOSIS: The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. RISK STRATIFICATION: Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced estimated glomerular filtration rate. RISK-ADAPTED THERAPY: For those patients with a dominant plasmacytoma, first-line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement should receive systemic therapy. Corticosteroids are temporizing, but alkylators and lenalidomide are the mainstays of treatment, the former either in the form of low-dose conventional therapy or as high-dose conditioning for stem cell transplantation. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Daratumumab combinations also appear promising based on case series. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.
引用
- Dispenzieri A. POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol. 2023. PMID: 37732822. doi:10.1002/ajh.27081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。